ERLOTINIB HCL
Product Quick Detail
- Minimum Order
- 1
- Packaging
- 25kg/drum
- Delivery
- 15 Days
Specifications
ERLOTINIB HCL
183321-74-6
C22H23N3O4
The small molecule compound, Erlotinib is a receptor tyrosine kinase inhibitor (EGFR antagonist) and belongs to molecular targeted therapy Drugs. It can inhibit the phosphorylation reaction
through competing with adenosine triphosphate to bind to the catalytic region of the receptor tyrosine kinase, thereby blocking the down-proliferation signaling and inhibiting the activity of the
tumor cell ligand-dependent HER-1/EGFR, thus achieving the inhibition of the proliferation of tumor cells. Clinically, it is mainly used in the treatment of incurable locally advanced or metastatic
non-small cell lung cancer (NSCLC) and being used in combination with gemcitabine for first-line treatment of locally advanced unresectable or metastatic pancreatic cancer.
- Country: China (Mainland)
- Business Type: Hangzhou Huisheng Biotech Pharmaceutical Co.,Ltd
- Market:The Middle East,Europea,Russia,and South America and US market
- Founded Year:2002
- Address:
- Contact:Tibi Teng
